-transparent.png){kind=logo}
The ability was tested of appropriate substituents of benzo[a]pyrene (BP) at C-6 to decrease or suppress the carcinogenic activity for these BP derivatives relative to the parent compound. 8-week-old female Swiss mice in 9 groups of 30 were treated on the back with 0.2 mumol of compound in acetone 4 times weekly for 20 weeks. The following compounds were administered: BP, 6-methylbenzo[a]pyrene (BP-6-CH3), 6-hydroxymethylbenzo[a]pyrene (BP-6-CH2OH), benzo[a]pyrene-6-carboxaldehyde (BP-6-CHO), benzo[a]pyrene-6-carboxylic acid, 6-methoxybenzo[a]pyrene, 6-acetoxybenzo[a]pyrene, 6-bromobenzo[a]pyrene, and 6-iodobenzo[a]pyrene. Two additional groups received BP or BP-6-CH3 twice weekly for 20 weeks at a total dose 25% of that above. In addition, the metabolism of selected 6-substituted BP derivatives was studied, using mouse skin homogenates in vitro and mouse skin in vivo. Only four compounds were carcinogenic; the order of potency was BP greater than BP-6-CH3 greater than BP-6-CH2OH and BP-6-CHO. The difference in carcinogenicity between BP-6-CH2OH and BP-6-CHO could not be assessed by this experiment. In a further tumorigenesis experiment the carcinogenicity of BP-6-CH2OH was compared to that of BP-6 CHO, BP-6-CH3 and 6-hydroxymethylbenzo[a]pyrere sulfate ester (BP-6-CH2OSO3Na) on mouse skin. 9-week-old female Swiss mice in groups of 28 were treated at three dose levels with 0.8, 0.2 and 0.05 mumol of compounds in dioxane--dimethyl sulfoxide (75 : 25) twice weekly for 40 weeks. After 40 experimental weeks BP-6-CH2OSO3Na proved to be a more potent carcinogen than BP-6-CH2OH, which, in turn was more active than BP-6-CHO. The greater carcinogenicity of BP-6-CH3 relative to BP-6-CH2OH and BP-6-CHO is confirmed, suggesting that BP-6-CH2OH is not a proximate carcinogenic metabolite for BP-6-CH3. Since BP-6-CHO is a weaker carcinogen than BP-6-CH2OH and is efficiently reduced metabolically to BP-6-CH2OH, the latter compound may be a common proximal carcinogenic metabolite. The stronger potency of BP-6-CH2OSO3Na, compared to its alcohol, suggests that an ester of BP-6-CH2OH might be the ultimate alkylating compound reacting with cellular nucleophiles.
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
September 1977,
Cancer research,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
December 1972,
British journal of cancer,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
March 1973,
Biochemical pharmacology,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
January 1976,
Proceedings of the National Academy of Sciences of the United States of America,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
January 1988,
Journal of cancer research and clinical oncology,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
July 1995,
Xenobiotica; the fate of foreign compounds in biological systems,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
August 1980,
Journal of medicinal chemistry,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
January 1988,
Journal of cancer research and clinical oncology,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
August 1977,
Cancer research,
E Cavalieri, and
R Roth, and
C Grandjean, and
J Althoff, and
K Patil, and
S Liakus, and
S Marsh
February 1980,
Cancer research,
